Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 27, 2025CancerOpen Access

Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single‐center validation study

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSabrina BarrièreCBCéline BourgneTTThomas Tassin

Discussion

Loading...

Member takes

Overview

Validation study shows improved prognostic value and sensitivity of WT1 monitoring in acute myeloid leukemia, highlighting its clinical significance.

Key Points

  • The revised WT1 threshold of seven copies improves prognostic value in acute myeloid leukemia with higher sensitivity.
  • This study demonstrates a 78.6% concordance rate with Nucleophosmin 1 mutations, indicating better MRD monitoring.
  • Statistical analyses employed include concordance, sensitivity, specificity, and Akaike information criterion comparisons.
  • Findings emphasize the importance of locally optimized thresholds for measurable residual disease in acute myeloid leukemia.

Cite This Study

Barrière et al. (2025) studied this question.

synapsesocial.com/papers/68ff87d8c8c50a61f2bdccadhttps://doi.org/10.1002/cncr.70140
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study2009 · 440 citations
  2. 2Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia2005 · 280 citations
  3. 3Recommended methods to compare the accuracy of two binary diagnostic tests subject to a paired design2019 · 17 citations
  4. 4Mutations in the Wilms' tumor gene WT1 in leukemias1996 · 172 citations
  5. 5The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia2022 · 32 citations